ArticleCurrent rheumatology reports2016
Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.
Article in Current rheumatology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04115423 (A Retrospective Cohort Study to Examine the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab Compared With Tumor Necrosis Factor Inhibitors Using the National Health Insurance Database), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Retrospective Cohort Study to Examine the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab Compared With Tumor Necrosis Factor Inhibitors Using the National Health Insurance Database
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Comparisons of infection events associated with tumor necrosis factor inhibitors in patients with inflammatory arthritis: A systematic review and network meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Value of Literature Review to Inform Development and Use of Biologics in Juvenile Idiopathic Arthritis.Frontiers in pediatrics · 2022Pooled it
- Severe Respiratory Infections in Rheumatoid Arthritis Patients: An Observational Study of 528 Patients from a Single University Hospital.Journal of clinical medicine · 2025Article
- Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis.Exploratory research in clinical and social pharmacy · 2023Article
- Dental Caries in Adult Patients with Rheumatoid Arthritis-A Systematic Review.Journal of clinical medicine · 2023Review
- Bronchiectasis is as crucial as interstitial lung disease in the severe pneumonia that occurs during treatment with biologic DMARDs in rheumatoid arthritis: a retrospective cohort study in a single facility.Rheumatology international · 2022Article
- COVID-19: Considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic.World journal of clinical cases · 2021Article
- Performance of the RABBIT infection risk score in an Argentinian rheumatoid arthritis cohort.Clinical rheumatology · 2021Article
- Managing rheumatic diseases during COVID-19.Clinical rheumatology · 2020Review
- Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic.The Korean journal of internal medicine · 2020Review
- Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.Annals of the rheumatic diseases · 2020Article
- [Acute exacerbation of the underlying disease or infection : Which diagnostics are warranted in patients with immunosuppressive treatment for inflammatory rheumatic diseases?]Zeitschrift fur Rheumatologie · 2019Review
- Applications of RNA interference in the treatment of arthritis.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Rare infection in patient with rheumatoid arthritis treated with adalimumab.BMJ case reports · 2019Article
- Incidence of infection other than tuberculosis in patients with autoimmune rheumatic diseases treated with bDMARDs: a real-time clinical experience from India.Rheumatology international · 2019Observational
- Article
- Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting.Frontiers in pharmacology · 2019Article
- Activity of rheumatoid arthritis correlates with oral inflammatory burden.Rheumatology international · 2018Article
- Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables.Therapeutics and clinical risk management · 2018Article
- RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus.Disease models & mechanisms · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biologic use is a major advance in the treatment of several autoimmune conditions, including rheumatoid arthritis. In this review, we summarize key studies of serious/hospitalized infections in rheumatoid arthritis (RA). RA is a risk factor for infections. High RA disease activity is associated with higher risk of serious infection. The risk of serious infections with tumor necrosis factor inhibitor (TNFi) biologics is increased in the first 6 months of initiating therapy, and this risk was higher compared to the use of traditional disease-modifying anti-rheumatic drugs (DMARDs). Emerging data also suggest that biologics may differ from each other regarding the risk of serious or hospitalized infections. Past history of serious infections, glucocorticoid dose, and older age were other important predictors of risk of serious infections in patients treated with biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.